Areteia Therapeutics introduces dexpramipexole, a novel oral drug in Phase 3 trials for asthma and COPD, aiming for approval ...

Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

Though smoking and increasing levels of pollution exposure are well recognised as causes of lung cancer the connection ...

Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

Researchers reported that a lung MRI technique that uses inhaled gas can identify early patchy lung defects in patients with ...

During the 43rd J.P. Morgan Annual Healthcare Conference last month, Areteia Therapeutics took centre stage, presenting a ...

Treatments were well tolerated with one adverse ... improved biological markers and clinical outcomes in patients with COPD exacerbations. It is speculated that the effect of NAC on inflammatory ...

Let's help them breathe easy again with natural solutions like PhytoRelief-Plus immunity lozenges, exercise, and a healthy ...

Finding it hard to breathe when you lay down is medically called orthopnea. Find a list of potential causes to help narrow ...

6, 2025 — Despite new medication ... finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...